Undisclosed ADC Program

About Antigenix Therapeutics

Antigenix Therapeutics is a preclinical biotech emerging from stealth with a $7 million seed round to advance its proprietary ADC platform. The company's technology centers on a patented antibody that targets a cancer-specific cell surface protein, aiming to deliver potent payloads with precision while sparing healthy tissue. Its initial focus is on developing therapies for cancers resistant to current treatments, with the goal of filing an IND and advancing its first candidates. The company is led by a team with expertise in ADC development, translational medicine, and biotech venture creation.

Therapeutic Areas